Thymidylate synthase (TS) is responsible for catalysing the de novo biosynthesis of doexythymidine monophosphate and is a target for many anticancer drugs. A series of thymidylate synthase inhibitors (TSIs), synthesised in our laboratory, were submitted to primary anticancer screening by the National Cancer Institute (NCI). Four compounds, 3,3bis(4-methoxyphenyl)-1H, 3H-naphtho[1,8-cd]pyran-1-one (MR7), 6-chloro-3,3-bis(4-hydroxyphenyl)-]H,3H-naphtho[1,8cdjpyran-1-one (MR21), 3,3-bis(3-fluoro-4-hydroxyphenyl)IH,3H-naphtho[1,8-cd]pyran-l-one (MR35) and 6-bromo-3,3bis(3-chloro-4-hydro.xyphenyl)-1H,3H-naphtho[1,8-cd]pyran-l- one (MR36), passed the criteria and were automatically scheduled for evaluation against the full panel of 60 human tumour cell lines. In this study, the antiproliferative activity of the substances against SK-MEL-2 cells (from metastatic tissue) and SK-MEL-28 cells (from primary malignant melanoma cells) was investigated. Neutral Red uptake and the MTT test were performed to confirm the results of the NCI, and [H-3]thymidine incorporation was performed as a test of the proliferation rate. Our results indicated that compounds MR21 and MR36 were the most active agents and the [H-3]-thymidine test was the best in predicting toxicity against melanoma cells.

Pharmacological and toxicological evaluation of a new series of thymidylate synthase inhibitors as anticancer agents / Benassi, Luisa; Magnoni, Cristina; Giudice, Stefania; Bertazzoni, Giorgia; Costi, Maria Paola; Rinaldi, Marcella; Venturelli, Alberto; A., Coppi; Rossi, Tiziana. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - STAMPA. - 26:(2006), pp. 3499-3504.

Pharmacological and toxicological evaluation of a new series of thymidylate synthase inhibitors as anticancer agents

BENASSI, Luisa;MAGNONI, Cristina;GIUDICE, Stefania;BERTAZZONI, Giorgia;COSTI, Maria Paola;RINALDI, Marcella;VENTURELLI, Alberto;ROSSI, Tiziana
2006

Abstract

Thymidylate synthase (TS) is responsible for catalysing the de novo biosynthesis of doexythymidine monophosphate and is a target for many anticancer drugs. A series of thymidylate synthase inhibitors (TSIs), synthesised in our laboratory, were submitted to primary anticancer screening by the National Cancer Institute (NCI). Four compounds, 3,3bis(4-methoxyphenyl)-1H, 3H-naphtho[1,8-cd]pyran-1-one (MR7), 6-chloro-3,3-bis(4-hydroxyphenyl)-]H,3H-naphtho[1,8cdjpyran-1-one (MR21), 3,3-bis(3-fluoro-4-hydroxyphenyl)IH,3H-naphtho[1,8-cd]pyran-l-one (MR35) and 6-bromo-3,3bis(3-chloro-4-hydro.xyphenyl)-1H,3H-naphtho[1,8-cd]pyran-l- one (MR36), passed the criteria and were automatically scheduled for evaluation against the full panel of 60 human tumour cell lines. In this study, the antiproliferative activity of the substances against SK-MEL-2 cells (from metastatic tissue) and SK-MEL-28 cells (from primary malignant melanoma cells) was investigated. Neutral Red uptake and the MTT test were performed to confirm the results of the NCI, and [H-3]thymidine incorporation was performed as a test of the proliferation rate. Our results indicated that compounds MR21 and MR36 were the most active agents and the [H-3]-thymidine test was the best in predicting toxicity against melanoma cells.
2006
26
3499
3504
Pharmacological and toxicological evaluation of a new series of thymidylate synthase inhibitors as anticancer agents / Benassi, Luisa; Magnoni, Cristina; Giudice, Stefania; Bertazzoni, Giorgia; Costi, Maria Paola; Rinaldi, Marcella; Venturelli, Alberto; A., Coppi; Rossi, Tiziana. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - STAMPA. - 26:(2006), pp. 3499-3504.
Benassi, Luisa; Magnoni, Cristina; Giudice, Stefania; Bertazzoni, Giorgia; Costi, Maria Paola; Rinaldi, Marcella; Venturelli, Alberto; A., Coppi; Rossi, Tiziana
File in questo prodotto:
File Dimensione Formato  
PHARMACOLOGICAL AND TOXICOLOGICAL TS 2006.pdf

Solo gestori archivio

Tipologia: Versione pubblicata dall'editore
Dimensione 240.98 kB
Formato Adobe PDF
240.98 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/305869
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact